Cathay Biotech

Cathay Biotech Equity

The The Equity of Cathay Biotech (688065.SS) as of Oct 17, 2026 is 21.22 B CNY. In the previous year, The Equity was 11.51 B CNY — a change of 84.38% (higher).

Equity

21.22 BCNY

YoY

84.38%

Last updated:

In 2025, Cathay Biotech's equity was 21.22 B CNY, a 84.38% increase from the 11.51 B CNY equity in the previous year.

The Cathay Biotech Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
3.16 B CNY
Jan 1, 2019
4.64 B CNY
Jan 1, 2020
10.38 B CNY
Jan 1, 2021
10.67 B CNY
Jan 1, 2022
10.95 B CNY
Jan 1, 2023
11.16 B CNY
Jan 1, 2024
11.51 B CNY
Jan 1, 2025
21.22 B CNY
The Cathay Biotech Equity history
YEAREquityYoY
21.22 BCNY+84.38%
11.51 BCNY+3.07%
11.16 BCNY+1.97%
10.95 BCNY+2.66%
10.67 BCNY+2.70%
10.38 BCNY+123.72%
4.64 BCNY+47.05%
3.16 BCNY+43.70%
2.20 BCNY+80.24%
1.22 BCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cathay Biotech Stock analysis

What does Cathay Biotech do? Cathay Biotech is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Cathay Biotech's Equity

Cathay Biotech's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Cathay Biotech's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Cathay Biotech's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Cathay Biotech's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Cathay Biotech’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Cathay Biotech stock

The Equity of Cathay Biotech is 21.22 B CNY in 2025.

The Equity of Cathay Biotech changed from 11.51 B CNY to 21.22 B CNY, representing a 84.38% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Cathay Biotech since 2006 – with annual values, charts, and detailed analysis.

The Equity's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Cathay Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Cathay Biotech

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Cathay Biotech